As your body adjusts to the medication, changes in blood sugar levels and appetite may lead to temporary energy fluctuations
Most individuals begin to see results within the first few weeks of treatment, but significant weight loss typically occurs over several months
If no USP monograph existsas is in the case of semaglutideFDA does not require the development of a new monograph for approval, but applicants should work with USP to create a monograph through the USP Pending Monograph Process (USP-PMP)
That said, retatrutide remains investigational and unlicensed, and the full safety data deserve careful scrutiny once peer-reviewed
LLY's Previous Phase III Wins With Retatrutide We remind investors that the success of the phase III TRIUMPH-2 and TRIUMPH-3 obesity studies marks the fourth and fifth positive phase III data readout for Eli Lilly's retatrutide
For broader context on peptide therapy, see our complete guide to peptide treatments